Press releases
Access archived Guidant press releases
Access archived BTG press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jul 12, 2013Device Facilitates Delivery of Interventional Devices in Complex PCI Procedures
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration 510(k) clearance and CE Mark approval for the Guidezilla™...
-
Jul 11, 2013
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2013 on...
-
Jun 28, 2013Transaction to Accelerate Boston Scientific Expansion in Growing Electrophysiology Market
In a move that would significantly boost its capabilities in the fast-growing market for advanced electrophysiology procedures, Boston Scientific...
-
Jun 26, 2013
Paris (June 26, 2013) – The first patient implant of the Boston Scientific Corporation (NYSE: BSX) VITALIOTM pacemaker was performed at ZGT Hengelo in Hengelo, the Netherlands. In addition...
-
Jun 25, 2013
Paris (June 25, 2013) – Boston Scientific Corporation (NYSE: BSX) is launching a new family of pacemakers in Europe. These pacemakers monitor respiration, adjust pacing accordingly, and...
-
Jun 24, 2013Outcomes Follow Recent NICE Guidance Supporting Safety and Effectiveness of Subcutaneous Implantable Defibrillators
Paris (June 24, 2013) – The Boston Scientific Corporation (NYSE:BSX) S-ICD® (subcutaneous implantable defibrillator) System showed a significant reduction in major lead-related...
-
Jun 18, 2013VANTAGE Study Interim Data Presented at International Congress of Parkinson's Disease and Movement Disorders in Sydney
Patients with Parkinson's disease using the Boston Scientific Corporation (NYSE: BSX) Vercise™ DBS (deep brain stimulation) System showed a...
-
Jun 17, 2013First Implant of Company's Vercise Deep Brain Stimulation Device Designed to Treat Parkinson's
Boston Scientific Corporation (NYSE: BSX) announces the first implantation of its Vercise™ DBS System as part of the INTREPID clinical trial. ...
-
Jun 3, 2013
Boston Scientific Corporation (NYSE: BSX) continues to demonstrate its commitment to women's health by providing a research and education grant of more...
-
May 27, 2013GUIDE DBS is the World's First Deep Brain Stimulation Visual Simulation System
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for use of the GUIDE™ DBS System, the world's first deep brain stimulation...
-
May 24, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 38th Annual Deutsche Bank 2013 Healthcare Conference on May 30 in Boston....
-
May 22, 2013Interim Data from REDUCE-HTN Clinical Program Presented Today at EuroPCR
Boston Scientific Corporation (NYSE: BSX) today reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained...
-
May 22, 2013New Data Presented In Late-Breaking Clinical Trial Session At EuroPCR Demonstrated Successful Deployment Of The Lotus™ Valve In The First 60 Patients With Minimal Paravalvular Regurgitation At 30 Days
Boston Scientific Corporation (NYSE: BSX) reports positive results from a pre-specified analysis of the first 60 patients enrolled in the REPRISE II trial...
-
May 22, 2013
Boston Scientific Corporation (NYSE: BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are...
-
May 21, 2013
Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial presented today demonstrated that the Boston Scientific Corporation (NYSE:...
-
May 17, 2013
Boston Scientific Corporation (NYSE:BSX) is scheduled to participate in Digestive Disease Week (DDW®) 2013, May 18-21 in Orlando, Fla. More than 24...
-
May 17, 2013
Boston Scientific Corporation (NYSE:BSX) is scheduled to participate at the annual EuroPCR Scientific Program May 21-24 in Paris. "We are pleased to...
-
May 15, 2013Study Evaluates Clinical Outcomes of Self-Expanding Metal Stents as a Bridge to Surgery
The first patient has been enrolled in a clinical investigation evaluating the use of the Boston Scientific Corporation (NYSE: BSX) WallFlex® Biliary...
-
May 10, 2013Industry-Leading Battery Life Reduces the Frequency of Replacement Surgery
New data from 100,438 patients with Boston Scientific Corporation (NYSE:BSX) implantable cardiac defibrillators (ICDs) and cardiac resynchronization...
-
May 10, 2013Company Offers Mapping System with IntellaMap Orion™ Mapping Catheter in Effort to Significantly Enhance Physician Treatment Options
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Rhythmia™ Mapping System, a next-generation 3D mapping and navigation...
-
May 9, 2013
Boston Scientific Corporation (NYSE: BSX) reports that the four-year follow-up data from the PROTECT AF clinical trial demonstrated the WATCHMAN® Left...
-
May 8, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2013 Healthcare Conference on May 15 in Las...
-
May 6, 2013
Boston Scientific Corporation (NYSE: BSX) completed a first-in-human clinical trial utilizing the IntellaTip MiFi™ XP Ablation Catheter for the...
-
May 3, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions...
-
Apr 25, 2013
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.761 billion and adjusted earnings per share of $0.16 for the first quarter ended March...